Saturday 17 October 2026
Export UPC’s income statement to Excel — free account
Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
3.97
0.18
−4.34%
Follow UPC
| Sep '18 | Dec '18 | Sep '19 | Dec '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 3 | 6 | 1 | 4 |
P/E ratio |
4.66 | 4.66 | 4.66 | — | 4.66 | 2,864.79 | 2,864.79 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | 5.02 | 1.78 | 0.89 | 0.35 | 0.63 |
P/S ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
9.91 | 9.91 | 9.68 | — | 10.16 | 11.66 | 6.91 | 3.19 | 3.87 | 7.37 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (1.75) | 0.74 | (3.74) | (3.05) | (1.91) | (2.56) |
P/B ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | (0.17) | 0.00 | (0.26) | (0.27) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 9.40 | 9.74 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | — | 0.00 | (0.95) | (3.92) | 0.02 | 3.57 | 1.54 |
EV/FCF |
0.00 | 0.00 | 0.00 | — | 0.00 | (0.95) | 2.00 | 0.02 | 3.37 | 1.47 |
Quick Ratio |
1.76 | 1.76 | 1.76 | 0.00 | 2.62 | 3.36 | 2.60 | 1.33 | 2.37 | 3.71 |
Current Ratio |
2.24 | 2.24 | 2.24 | 0.00 | 2.91 | 4.50 | 3.17 | 1.84 | 2.54 | 4.07 |
Net Debt/EBITDA |
(0.05) | (0.31) | (0.06) | 0.00 | (0.70) | (1.24) | 2.16 | (0.06) | 2.85 | 10.15 |
Debt/Assets |
14.69% | 0.00% | 14.14% | 0.00% | 9.19% | 6.18% | 6.61% | 13.14% | 11.76% | 13.36% |
Debt/Equity |
0.21 | 0.00 | 0.20 | — | 0.13 | 0.07 | 0.08 | 0.20 | 0.18 | 0.16 |
Asset Turnover |
3.73 | 1.86 | 1.86 | 0.00 | 1.55 | 0.97 | 0.62 | 0.64 | 0.42 | 0.26 |
Operating CF/Net income |
0.59 | 0.00 | 1.75 | 0.00 | 0.81 | (0.18) | 0.15 | (0.17) | 1.09 | 1.38 |
Capex/Depreciation |
0.00 | — | (0.21) | — | (0.13) | (24.78) | (0.17) | (0.09) | (0.74) | (0.66) |
Interest Coverage |
80.21 | 80.21 | 75.43 | — | 82.81 | 133.76 | (45.81) | (25.29) | (28.83) | (12.57) |
| 68.45% | 122.18% | 81.35% | 0.00% | 45.55% | 28.39% | (16.58%) | (17.69%) | (23.76%) | (7.23%) | |
| 84.67% | 42.34% | 42.34% | 52.65% | 38.10% | 22.88% | (13.47%) | (13.00%) | (15.91%) | (5.35%) | |
ROIC |
54.80% | 70.41% | 51.97% | 0.00% | 47.85% | 20.48% | (14.75%) | (8.80%) | (20.89%) | (5.73%) |
Return on Tangible Assets |
66.57% | 66.57% | 66.57% | 69.52% | 38.35% | 25.76% | (26.75%) | (43.25%) | (25.01%) | (8.34%) |
Average Days of Receivables |
70.53 | 70.53 | 70.53 | 0.00 | 129.24 | 120.27 | 138.06 | 146.83 | 294.42 | 312.48 |
Research and Development Expense of Revenue |
2.30% | 0.00% | 1.86% | — | 1.90% | 11.39% | 19.04% | 15.04% | 13.16% | 3.76% |
Selling, General and Administrative Expense of Revenue |
9.14% | 9.14% | 9.14% | 0.00% | 10.61% | 13.07% | 54.02% | 29.16% | 48.04% | 47.85% |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
21.47% | 21.47% | 21.47% | — | 21.47% | 0.03% | 0.03% | (0.19%) | (1.00%) | (34.76%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
9.04 | 0.00 | 7,552.11 | — | 6,978.18 | 9,053.21 | 6,690.53 | 5,384.78 | 1,656.44 | 39.17 |
Operating CF per Share |
1.21 | — | 3,000.86 | — | 1,389.82 | (387.89) | (218.72) | 186.13 | (683.94) | (11.08) |
Capex per Share |
0.00 | — | (19.55) | — | (11.77) | (2,089.36) | (15.53) | (7.37) | (25.99) | (0.75) |
Free Cash Flow per Share |
1.21 | — | 2,981.32 | — | 1,378.05 | (2,477.25) | (234.25) | 178.77 | (709.93) | (11.83) |
Cash per Share |
0.86 | 0.00 | 722.11 | — | 2,285.95 | 4,113.79 | 3,143.35 | 880.87 | 2,122.14 | 73.68 |
Shareholders Equity per Share |
3.37 | 0.00 | 2,814.57 | — | 4,727.93 | 11,119.70 | 7,740.38 | 4,661.70 | 3,273.59 | 123.12 |
Interest Debt per Share |
0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.37 | 0.00 | 2,814.57 | — | 4,727.93 | 11,119.70 | 7,740.38 | 4,661.70 | 3,273.59 | 123.12 |
Free Cash Flow |
4.46 | — | 13.12 | — | 6.06 | (13.13) | (1.41) | 1.07 | (9.87) | (5.39) |
Working Capital |
6.78 | 6.78 | 6.78 | 10.87 | 15.28 | 39.27 | 28.41 | 11.52 | 31.32 | 40.43 |
Capital Expenditures |
(0.15) | — | (0.09) | — | (0.05) | (11.07) | (0.09) | (0.04) | (0.36) | (0.34) |
Net Current Asset Value |
6.78 | 6.78 | 6.78 | 10.87 | 15.28 | 39.27 | 28.41 | 11.52 | 29.19 | 40.43 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.23 | 0.00 | 0.00 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.00 | 0.09 | — | 0.09 | 0.10 | 0.13 | 0.14 | 0.14 | 0.14 |
Cash ROIC |
24.51% | 0.00% | 72.54% | — | 18.10% | (15.43%) | (2.03%) | 2.77% | (11.89%) | (5.45%) |
Accounts Receivable Turnover |
4.73 | 5.18 | 5.18 | 0.00 | 2.82 | 3.60 | 2.59 | 2.29 | 1.46 | 1.05 |
Accounts Payable Turnover |
8.13 | 0.00 | 8.13 | — | 7.18 | 5.66 | 4.35 | 5.74 | 3.57 | 3.51 |
Inventory Turnover |
3.69 | 7.58 | 7.58 | — | 7.35 | 10.37 | 7.82 | 7.93 | 6.67 | 5.88 |
Average Days of Payables |
54.10 | 0.00 | 35.67 | — | 59.14 | 85.56 | 61.50 | 76.10 | 105.82 | 52.73 |
Days of Inventory on Hand |
48.16 | 48.16 | 48.16 | — | 41.89 | 39.67 | 44.13 | 55.48 | 37.40 | 69.26 |
Average Receivables |
7.03 | 6.42 | 6.42 | 8.65 | 10.87 | 13.34 | 15.50 | 14.09 | 15.78 | 16.93 |
Average Payables |
2.44 | — | 2.44 | — | 2.31 | 4.00 | 4.19 | 3.83 | 4.75 | 3.29 |
Average Inventory |
5.37 | 2.62 | 2.62 | — | 2.26 | 2.18 | 2.33 | 2.77 | 2.54 | 1.97 |
Average Assets |
8.92 | 17.84 | 17.84 | 14.35 | 19.84 | 49.47 | 64.84 | 50.63 | 54.84 | 68.63 |
Average Common Equity |
11.03 | 6.18 | 9.28 | — | 16.59 | 39.87 | 52.69 | 37.21 | 36.74 | 50.82 |
Columns are period end dates